ACC, AHA Issue Updated Chest Pain Data Standards

Chest pain is one of the leading reasons for adult emergency room visits in the United States, accounting for more than 7 million visits annually. Properly identifying and treating dangerous and life-threatening causes of chest pain is critical.

The 2021 American Heart Association/American College of Cardiology Guideline for the Evaluation and Diagnosis of Chest Pain underscored the need to reach a consensus for the definitions of chest pain. In an update to the 2021 guideline, this 2022 document standardizes related data elements for consistent reporting on chest pain cases and establishes a new definition set focusing on serious cardiovascular causes of chest pain and acute myocardial infarction.

Included in the document, data elements are grouped into three broad categories: chest pain, myocardial injury and myocardial infarction. Chest pain symptoms have traditionally been labeled “typical” or “atypical,” however, to define their expansive nature, the document divides chest pain syndromes into three categories: “cardiac,” “possible cardiac” and “noncardiac” based on the 2021 chest pain guideline. In addition, the writing committee writes that uniform definitions for myocardial infarction are needed to ensure accurate reporting of cardiac events across all clinical trials and registries. Data elements for procedure-related myocardial injury and procedure-related myocardial infarction are included in the document. The standardized definitions and data elements should be broadly applicable across patient care settings, electronic health records, quality and performance improvement initiatives, registries and public reporting programs.

The 2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction will publish online in the Journal of the American College of Cardiology and Circulation: Cardiovascular Quality and Outcomes on Tuesday, August 30, 2022 at 2:00 p.m. ET. It was developed in collaboration with the American College of Emergency Physicians and the Society for Cardiac Angiography and Interventions, and endorsed by the Society for Academic Emergency Medicine.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version